647 related articles for article (PubMed ID: 9585350)
1. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
2. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
Bentlage C; Nikkhah G; Cunningham MG; Björklund A
Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
[TBL] [Abstract][Full Text] [Related]
3. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
4. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Bouchez G; Sensebé L; Vourc'h P; Garreau L; Bodard S; Rico A; Guilloteau D; Charbord P; Besnard JC; Chalon S
Neurochem Int; 2008 Jun; 52(7):1332-42. PubMed ID: 18372079
[TBL] [Abstract][Full Text] [Related]
5. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
6. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
7. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC
Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114
[TBL] [Abstract][Full Text] [Related]
8. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
9. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
[TBL] [Abstract][Full Text] [Related]
10. Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions.
Pickel VM; Chan J; Nirenberg MJ
Synapse; 2002 Aug; 45(2):113-24. PubMed ID: 12112404
[TBL] [Abstract][Full Text] [Related]
11. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Agrawal AK
Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
[TBL] [Abstract][Full Text] [Related]
12. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
[TBL] [Abstract][Full Text] [Related]
13. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons.
González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M
J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
Bilbao G; Ruiz-Ortega JA; Miguens N; Ulibarri I; Linazasoro G; Gómez-Urquijo S; Garibi J; Ugedo L
Brain Res; 2006 Apr; 1084(1):175-84. PubMed ID: 16574080
[TBL] [Abstract][Full Text] [Related]
16. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
17. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
18. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system.
Ferrario JE; Taravini IR; Mourlevat S; Stefano A; Delfino MA; Raisman-Vozari R; Murer MG; Ruberg M; Gershanik O
J Neurochem; 2004 Sep; 90(6):1348-58. PubMed ID: 15341519
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
20. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra.
Hersch SM; Yi H; Heilman CJ; Edwards RH; Levey AI
J Comp Neurol; 1997 Nov; 388(2):211-27. PubMed ID: 9368838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
